{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:18:31Z","timestamp":1783505911832,"version":"3.55.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"BMBF","doi-asserted-by":"publisher","award":["01GN2537"],"award-info":[{"award-number":["01GN2537"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["M0166"],"award-info":[{"award-number":["M0166"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["6908\/4-1"],"award-info":[{"award-number":["6908\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Renal Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Hypercholesterolemia is a major driver of cardiovascular disease, a leading cause of premature mortality in patients with chronic kidney disease (CKD). Despite their typically young age, patients with Alport syndrome (AS), the second most prevalent genetic cause of CKD, may face a disproportionately high risk of hypercholesterolemia. This study investigates whether increased albuminuria precipitates hyperlipidemia in this population to a degree comparable with general CKD cohorts, while further delineating the risk factors underlying this development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter, observational, non-interventional, and retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 459 patients with AS, 59.3% had hypercholesterolemia and 58.5% had elevated low-density lipoprotein cholesterol (LDL-C). Despite lower estimated glomerular filtration rate (eGFR) and higher albuminuria, patients receiving lipid-lowering therapy (LLT) had significantly lower total cholesterol levels compared to the untreated patients (193.6 \u00b1 55.2 mg\/dl vs. 208.2 \u00b1 51.0 mg\/dl; P\u00a0=.044). Similarly, LDL-C levels were significantly lower in the treatment group (111.6 \u00b1 51\u00a0mg\/dl, n = 59) compared with the untreated group (124.3 \u00b1 40.2 mg\/dl, n =\u00a0238; P\u00a0=.041). Multivariable regression analysis adjusted for age, sex body mass index (BMI), eGFR, and LLT revealed that albuminuria was a significant independent predictor of total cholesterol (\u03b2 = 0.315; P &amp;lt;\u00a0.001) and LDL-C levels (\u03b2 = 0.242; P &amp;lt; .001). Male sex was associated with significantly higher LDL-C and lower high-density lipoprotein cholesterol (HDL-C) levels. Conversely, eGFR and BMI were not significant predictors of cholesterol levels. This association was also observed in the pediatric cohort (n =\u00a044), where albuminuria was the only independent predictor of cholesterol (\u03b2 = 0.728; P &amp;lt;\u00a0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hypercholesterolemia is highly prevalent in young patients with AS and is primarily driven by the severity of albuminuria, rather than other risk factors such as obesity or eGFR decline. These findings highlight a critical gap in current guidelines, support the implementation of early lipid screening and suggest that risk-adapted management may be necessary to prevent long-term cardiovascular complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag100","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:45:00Z","timestamp":1778845500000},"source":"Crossref","is-referenced-by-count":0,"title":["Albuminuria drives hyperlipidemia in patients with Alport syndrome"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8852","authenticated-orcid":false,"given":"Oliver","family":"Gross","sequence":"first","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen , Goettingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Jens","sequence":"additional","affiliation":[{"name":"corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Nephrology and Medical Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Cerkauskaite-Kerpauskiene","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephro-Urology and Surgery, Faculty of Medicine, Vilnius University , Vilnius ,","place":["Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Gillion","sequence":"additional","affiliation":[{"name":"Nephrology Department, Cliniques Universitaires Saint-Luc , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Choi","sequence":"additional","affiliation":[{"name":"corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Nephrology and Medical Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-9880","authenticated-orcid":false,"given":"Jan","family":"Halbritter","sequence":"additional","affiliation":[{"name":"corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Nephrology and Medical Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, , Berlin ,","place":["Germany"]},{"name":"Renal Division, University Freiburg Medical Center, Faculty of Medicine, University of Freiburg , Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pediatrics, , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pediatrics, , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pediatrics, , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilva","family":"Bever","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen , Goettingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Wenzlitschke","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen , Goettingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8510-2345","authenticated-orcid":false,"given":"Kathleen J","family":"Claes","sequence":"additional","affiliation":[{"name":"UZ Leuven Department of Nephrology and Renal Transplantation, , Leuven ,","place":["Belgium"]},{"name":"KU Leuven Department of Microbiology, Immunology, and Transplantation, Nephrology and Renal Transplantation Research Group, , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Wallbach","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen , Goettingen ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK) , Partner Site G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Boeckhaus","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen , Goettingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026070805490449900_bib1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2026070805490449900_bib2","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1111\/j.1523-1755.2005.09916.x","article-title":"Dyslipidemia and the progression of renal disease in chronic renal failure patients","volume":"68","author":"Cases","year":"2005","journal-title":"Kidney Int"},{"key":"2026070805490449900_bib3","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1053\/ajkd.1998.v32.pm9820472","article-title":"Hyperlipidemia in patients with chronic renal disease","volume":"32","author":"Kasiske","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2026070805490449900_bib4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.amjcard.2006.01.079","article-title":"Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States","volume":"98","author":"Wong","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026070805490449900_bib5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2215\/CJN.03110319","article-title":"Change in dyslipidemia with declining glomerular filtration rate and increasing proteinuria in children with CKD","volume":"14","author":"Saland","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026070805490449900_bib6","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and Type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N Engl J Med"},{"key":"2026070805490449900_bib7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00467-018-3985-4","article-title":"Expert consensus guidelines for the genetic diagnosis of Alport syndrome","volume":"34","author":"Savige","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2026070805490449900_bib8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2215\/CJN.10581014","article-title":"Ocular features in Alport syndrome: pathogenesis and clinical significance","volume":"10","author":"Savige","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026070805490449900_bib9","first-page":"1157","article-title":"A mutation causing Alport syndrome with tardive hearing loss is common in the western United States","volume":"58","author":"Barker","year":"1996","journal-title":"Am J Hum Genet"},{"key":"2026070805490449900_bib10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/life10120360","article-title":"Characterization of sensorineural hearing loss in children with Alport syndrome","volume":"10","author":"Boeckhaus","year":"2020","journal-title":"Life"},{"key":"2026070805490449900_bib11","first-page":"gfac006","article-title":"Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study","author":"Boeckhaus","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026070805490449900_bib12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"key":"2026070805490449900_bib13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"key":"2026070805490449900_bib14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2026070805490449900_bib15","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","article-title":"Lipoproteins in chronic kidney disease: from bench to bedside","volume":"42","author":"Speer","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070805490449900_bib16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2369-14-132","article-title":"Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001\u20132010","volume":"14","author":"Kuznik","year":"2013","journal-title":"BMC Nephrol"},{"key":"2026070805490449900_bib17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1476-9255-7-54","article-title":"Hypercholesterolemia and microvascular dysfunction: interventional strategies","volume":"7","author":"Stapleton","year":"2010","journal-title":"J Inflamm"},{"key":"2026070805490449900_bib18","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070805490449900_bib19","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents : summary Report","volume":"128","author":"Expert panel on integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","year":"2011","journal-title":"Pediatrics"},{"key":"2026070805490449900_bib20","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and Estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026070805490449900_bib21","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.ekir.2025.02.036","article-title":"Prospective cohort study in Alport syndrome patients under standard therapy","volume":"10","author":"Gross","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026070805490449900_bib22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int"},{"key":"2026070805490449900_bib23","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026070805490449900_bib24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/1440-1681.13556","article-title":"Renal lipotoxicity: insights from experimental models","volume":"48","author":"Castro","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026070805490449900_bib25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.34067\/KID.0006152020","article-title":"Podocyte Lipotoxicity in CKD","volume":"2","author":"Kim","year":"2021","journal-title":"Kidney360"},{"key":"2026070805490449900_bib26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000075925","article-title":"Cellular lipid metabolism and the role of lipids in progressive renal disease","volume":"24","author":"Abrass","year":"2004","journal-title":"Am J Nephrol"},{"key":"2026070805490449900_bib27","first-page":"209","article-title":"Lipid homeostasis, lipotoxicity and the metabolic syndrome","volume":"1801","author":"Unger","year":"2010","journal-title":"Biochim Biophys Acta BBA\u2014Mol Cell Biol Lipids"},{"key":"2026070805490449900_bib28","first-page":"1062","article-title":"Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome","volume":"22","author":"Koepke","year":"2007","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc\u2014Eur Ren Assoc"},{"key":"2026070805490449900_bib29","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2026070805490449900_bib30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070805490449900_bib31","doi-asserted-by":"publisher","first-page":"iv124","DOI":"10.1093\/ndt\/gfu028","article-title":"Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies","volume":"29","author":"Gross","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026070805490449900_bib32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/ndt\/gfae265","article-title":"Diagnosis, management and treatment of the Alport syndrome\u20132024 guideline on behalf of ERKNet, ERA and ESPN","volume":"40","author":"Torra","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026070805490449900_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2352-4642(25)00334-7","article-title":"Assessment, prevention, and management of cardiovascular disease risk factors in children with chronic kidney disease, on dialysis and after transplantation: clinical practice recommendations from the European Society for Paediatric Nephrology","volume":"10","author":"Stabouli","year":"2026","journal-title":"Lancet Child Adolesc Health"},{"key":"2026070805490449900_bib34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/archinte.167.10.999","article-title":"Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis","volume":"167","author":"Kodama","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026070805490449900_bib35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM200007063430103","article-title":"Primary prevention of coronary heart disease in women through diet and lifestyle","volume":"343","author":"Stampfer","year":"2000","journal-title":"N Engl J Med"},{"key":"2026070805490449900_bib36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/CIRCULATIONAHA.106.621417","article-title":"Healthy lifestyle factors in the primary prevention of coronary heart disease among men","volume":"114","author":"Chiuve","year":"2006","journal-title":"Circulation"},{"key":"2026070805490449900_bib37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults\u2013an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2026070805490449900_bib38","first-page":"gfae180","article-title":"Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport","author":"Gross","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026070805490449900_bib39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","article-title":"Patient adherence and medical treatment outcomes: a meta-analysis","volume":"40","author":"Robin\u00a0DiMatteo","year":"2002","journal-title":"Med Care"},{"key":"2026070805490449900_bib40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00467-025-07053-0","article-title":"High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometry","volume":"41","author":"Boeckhaus","year":"2026","journal-title":"Pediatr Nephrol"},{"key":"2026070805490449900_bib41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/adc.2009.175125","article-title":"A systematic review of interventions to enhance medication adherence in children and adolescents with chronic illness","volume":"95","author":"Dean","year":"2010","journal-title":"Arch Dis Child"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag100\/68292515\/gfag100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag100\/68292515\/gfag100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:49:08Z","timestamp":1783504148000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag100\/8678858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag100","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"gfag100"}}